Experimental vaccine targets Hard-to-Treat cancers
NCT ID NCT05964361
First seen Jun 15, 2026 · Last updated Jun 15, 2026
Summary
This early-stage trial tested a new type of cancer vaccine in 10 people with advanced cancers of the esophagus, pancreas, liver, or ovaries. The vaccine was made from each patient's own immune cells and designed to help their body fight the tumor. The main goals were to see if the vaccine could be safely made and given, and to check for any side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LIVER CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Antwerp University Hospital
Edegem, 2650, Belgium
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.